Cipla (CIPLA) · mywealthgrid

Loading page…

About

Cipla is a respiratory-led pharmaceutical company with a market cap of ₹1,17,450 crore and established presence in India and Africa. The company operates at a 20.89% operating margin with a lean balance sheet (D/E 0.01), positioning it as a scaled player in Indian generics.

Founded: 1935
Face value: ₹2

Market cap

₹1,08,864 Cr

P/E

32.3×

P/B

3.2×

Dividend yield

2.2%

ROE

11.8%

ROCE

16.5%

Debt / equity

0.01

OPM

20.9%

EPS (TTM)

₹41.7

Book value

₹426.2

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Operating margin volatility from 13.47% (Mar 2026) to 29.14% (Sep 2025) indicates thin margins in off-peak quarters; a revenue contraction would rapidly compress profitability.
FII stake declined from 22.56% to 20.21% in three months, potentially signalling foreign investor concerns; verify reasons for outflow.
High PE of 34.84 combined with 1y return of −2.75% suggests valuation stretched relative to recent stock performance.
Verify: patent expiry calendar on key respiratory products, generic competition intensity in India and Africa, regulatory pricing pressure.

Generated analysis · source review pending

Growth drivers

Respiratory franchise peaked at OPM 29.14% in Sep 2025, suggesting seasonal demand strength; verify if seasonal performance repeats and whether driven by market-share gains or demand recovery.
DII stake rose from 31.7% to 34.35% over three months, signalling domestic institutional confidence; verify if this reflects fundamental strength or tactical accumulation.
Very low leverage (D/E 0.01) provides financial flexibility for strategic investments or acquisitions; verify capex or M&A plans.
Africa franchise operates in underpenetrated healthcare market; verify revenue contribution, growth trajectory, and competitive positioning.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹1,344.0-2.6%1Y

Quick read

rule-based

Pros

+High return on capital employed of 20.9%
+Healthy operating margin of 20.9%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 102.1×
+Dividend payout of 69.7% of profit

Cons

−Modest revenue growth of 8% a year over the last 5 years

Research score

Structured signal from quality, growth, valuation and momentum.

46/100

Business quality: 64
Growth: 23
Valuation

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY 50 NIFTY 100 NIFTY 200 NIFTY 500 NIFTY TOTAL MARKET

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Sun Pharmaceutical IndustriesSUNPHARMASUNPHARMA	₹4,32,240 Cr	₹4,36,322 Cr	₹59,911 Cr	₹17,847 Cr	30.3%	₹12,096 Cr	19.7%	20.9%	14.7%	228
Divi's LaboratoriesDIVISLABDIVISLAB	₹2,45,561 Cr	₹2,45,561 Cr	₹11,230 Cr	₹3,967 Cr	32.6%	₹2,925 Cr	24.3%	20.8%	16.2%	348
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Apollo Hospitals EnterpriseAPOLLOHOSPAPOLLOHOSP	₹1,16,960 Cr	₹1,22,618 Cr	₹26,430 Cr	₹4,010 Cr	14.9%	₹2,090 Cr	7.9%	19.4%	21.9%	3
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
CiplaCIPLACIPLA	₹1,08,864 Cr	₹1,09,122 Cr	₹28,324 Cr	₹5,297 Cr	20.9%	₹3,371 Cr	13.7%	16.5%	11.8%	202
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Dr. Reddy's LaboratoriesDRREDDYDRREDDY	₹1,00,682 Cr	₹1,06,975 Cr	₹33,228 Cr	₹5,140 Cr	19.2%	₹3,222 Cr	12.3%	14.8%	11.7%	247
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Max Healthcare Institute LimitedMAXHEALTHMAXHEALTH	₹91,573 Cr	₹95,052 Cr	₹8,712 Cr	₹2,318 Cr	26.8%	₹1,457 Cr	17.2%	13.8%	14.3%	-110

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	14,630	15,219	16,362	17,132	19,160	21,763	22,753	25,774	27,548	28,163
COGS	5,317	5,438	5,784	5,991	7,352	8,496	8,252	8,820	8,929	9,549
Gross profit	9,313	9,781	10,578	11,141	11,808	13,268	14,501	16,955	18,619	18,613
	—	—	—	7,982	7,568	8,728	9,476	10,665	11,513	12,739
	—	—	—	3,159	4,240	4,540	5,024	6,289	7,106	5,875
OPM %	—	—	—	18.4%	22.1%	20.9%	22.1%	24.4%	25.8%	20.9%
Depreciation	—	—	—	1,175	1,068	1,052	1,172	1,051	1,107	1,211
Interest	159	114	168	197	161	106	110	90	62	54
	306	435	529	344	266	99	293	552	862	606
Profit before tax	1,222	1,669	2,079	2,131	3,277	3,480	4,036	5,700	6,799	5,216
Tax	—	250	570	631	889	934	1,203	1,547	1,530	1,354
Tax %	—	15%	27.4%	29.6%	27.1%	26.8%	29.8%	27.1%	22.5%	26%
	1,035	1,417	1,492	1,500	2,389	2,547	2,833	4,154	5,269	3,862
PAT margin %	7.1%	9.3%	9.1%	8.8%	12.5%	11.7%	12.5%	16.1%	19.1%	13.7%
EPS (₹)	—	—	—	19.2	29.8	31.2	34.7	51.1	65.3	48
EPS adjusted (₹)	12.5	17.5	19	19.2	29.8	31.2	34.7	51.1	65.3	48
	—	—	—	15.6%	16.8%	16%	24.5%	25.5%	24.5%	27.1%
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	161	161	161	161	161	161	161	161	161	162	162
Reserves	10,485	12,383	14,068	14,851	15,602	18,165	20,680	23,246	26,545	31,032	34,270
Minority interest	332	438	352	332	294	259	276	306	96	96	88
	1,702	4,113	4,098	4,316	2,816	1,756	824	520	247	92	258
	2,968	3,943	4,181	4,303	4,789	4,811	5,160	5,229	5,668	6,006	7,718
Total equity & liabilities	15,647	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387	42,496
	6,730	9,490	9,949	9,547	9,236	9,056	9,296	9,101	9,494	9,895	12,434
CWIP	535	719	512	331	421	571	383	689	864	1,213	1,586
Investments	639	973	1,259	2,554	1,471	2,710	2,551	3,722	5,563	8,044	8,223
	7,743	9,855	11,140	11,532	12,535	12,815	14,871	15,951	16,797	18,235	20,252
Total assets	15,647	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387	42,496

Segment results

As reported in NSE results XBRL. Segment result is before tax and finance costs.

Source XBRL ↗

Latest reported period · 31 Mar 2025 · ₹ crore

Segment	Revenue	Result	Assets	Liabilities
Pharmaceuticals	26,446.33	6,872.29	0	0
New ventures	1,303.36	10.53	0	0

SegmentFigure

New Ventures · revenue

₹ crore by fiscal year

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	64.6%	65%	61.6%	61%	63.7%	65.8%	67.6%	66.1%
EBITDA margin %	—	18.7%	22.2%	20.9%	22.1%	24.4%	25.9%	20.9%
EBIT margin %	—	11.9%	16.6%	16.1%	16.9%	20.3%	21.9%	16.6%
PAT margin %	9.1%	8.8%	12.5%	11.7%	12.5%	16.1%	19.1%	13.7%
Working capital
Receivable days	93	83	66	57	65	68	73	73
Inventory days	250	267	232	230	228	217	231	252
Payable days	2	5	3	8	109	102	116	123
NWC days	341	345	294	280	184	182	188	202
Leverage
Current ratio	3.29	2.66	2.87	2.99	3.34	3.7	4.24	3.44
Debt to EBITDA	—	0.88	0.41	0.18	0.1	0.04	0.01	0.04
Debt to equity	0.29	0.18	0.1	0.04	0.02	0.01	0	0.01
Interest coverage	2.8	12	21.5	35.6	39.5	66.6	111	102.1
Asset turnover	0.68	0.72	0.76	0.8	0.77	0.79	0.74	0.66
Return ratios
Return on assets %	6.2%	6.3%	9.5%	9.4%	9.6%	12.7%	14.1%	9.1%
Return on capital employed %	2.4%	12%	17.3%	17.7%	18.6%	23.1%	23.2%	16.5%
Return on equity %	9.9%	9.5%	13%	12.2%	12.1%	15.6%	16.9%	11.2%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	33.47%	33.47%	33.47%	30.91%	30.92%	29.19%	29.2%	29.19%	29.21%	29.21%	29.21%	29.21%
	25.74%	25.73%	25.83%	27.81%	28.8%	26.65%	26.28%	25.24%	24.55%	23.93%	22.56%	20.21%
	24.18%	24.33%	24.42%	24.95%	24.16%	27.71%	28.15%	29.26%	29.98%	30.45%	31.7%	34.35%
	0%	0%	0%	0%	0%	0%	0%	0%	0.27%	0.27%	0.27%	0.28%
	16.61%	16.47%	16.28%	16.33%	16.12%	16.45%	16.37%	16.31%	15.99%	16.14%	16.26%	15.95%
No. of shareholders	—	—	—	—	—	—	—	—	5,34,587	5,40,521	5,84,217	5,78,679

Promoter holding down 4.26 percentage points since Sep 2023.

1 disclosure

Person	Deal	Shares	Value	Holding	Filed
Anusha Jain jointly with Dinesh JainImmediate relative	BuyGift	15,419	₹0	0.00% → 0.00%	1 Oct 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

149 deals · 23 Sept 2021 – 16 Oct 2025

Date	Client	Type	Venue	Side	Quantity	Price	Value
16 Oct 2025	GOLDMAN SACHS BANK EUROPESE - ODI	Block	NSE	Buy	91,604	₹1,565.00	₹14.34 Cr
16 Oct 2025	GOLDMAN SACHS (SINGAPORE) PTE.- ODI	Block	NSE	Sell	91,604	₹1,565.00	₹14.34 Cr
14 Jul 2025	THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828	Block	NSE	Sell	1,56,532	₹1,485.00	₹23.25 Cr
14 Jul 2025	THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849	Block	NSE	Buy	1,56,532	₹1,485.00	₹23.25 Cr
2 Dec 2024	SAMINA HAMIED	Block	NSE	Sell	89,54,750	₹1,518.75	₹1,360.00 Cr
2 Dec 2024	SAMINA HAMIED	Bulk	NSE	Sell	89,54,750	₹1,518.75	₹1,360.00 Cr
2 Dec 2024	RUMANA HAMIED	Bulk	NSE	Sell	49,43,250	₹1,518.75	₹750.76 Cr
2 Dec 2024	RUMANA HAMIED	Block	NSE	Sell	49,43,250	₹1,518.75	₹750.76 Cr
2 Dec 2024	GOVERNMENT OF SINGAPORE	Block	NSE	Buy	24,03,202	₹1,518.75	₹364.99 Cr
2 Dec 2024	DSP MUTUAL FUND	Block	NSE	Buy	22,25,347	₹1,518.75	₹337.97 Cr

1–10 of 149

1 / 15

Mr. Y K HamiedNon-Executive - Non Independent Director-Chairperson related to Promoter
Mr. Achin GuptaExecutive Director-CEO-MD
Mr. Adil ZainulbhaiNon-Executive - Non Independent Director
Mr. Prathivadibhayankara Rajagopalan RameshNon-Executive - Independent Director
Mr. Mandar Purushottam VaidyaNon-Executive - Independent Director
Mr. Balram BhargavaNon-Executive - Independent Director
Ms. Sharmila ParanjpeNon-Executive - Independent Director
Mr. Abhijit Jagdish JoshiNon-Executive - Non Independent Director
Mr. Kamil HamiedNon-Executive - Non Independent Director
Ms. Maya HariNon-Executive - Independent Director
Mr. Dinesh JainChief Financial Officer

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

End of day 30 Sept 2026 · underlying ₹1,346.0 · volume and open interest in contracts

3

Expiry	Close	Chg	% Chg	Settlement	Open interest	Change in OI	Volume	Lot size
27 Oct 2026	₹1,357.2	-31.6	-2.3%	₹1,357.2	19,123	-55	1,519	425
23 Nov 2026	₹1,364.4	-23.5	-1.7%	₹1,364.4	3,758	+22	62	425
29 Dec 2026	₹1,374.2	-25.6	-1.8%	₹1,374.2	3	+3	5	425

Open the chart icon on a row for that contract's close over 103 stored sessions, with open interest as bars beneath it.

40

27 Oct 2026 23 Nov 2026 29 Dec 2026

Calls				Strike	Puts
OI	Chg OI	Volume	LTP	—	LTP	Volume	Chg OI	OI
1	0	0	₹229.6	1,160

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

160

across 20 fund houses

Held by these funds

12.81%

of the company's equity

All mutual funds

20.56%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

160 schemes · 20 fund houses

		Shares
Parag Parikh Flexi Cap Fund	PPFAS Mutual Fund	1.44 Cr	2,022.43	1.37%	1.772%	-0
Nifty 50 ETF	SBI Mutual Fund	1.09 Cr	1,538.04	0.72%	1.347%	+57,391
Value Fund	ICICI Prudential Mutual Fund	55.49 L	782.02	1.3%	0.685%	-0
ELSS Tax Saver Fund	SBI Mutual Fund	47.57 L	670.31	2.11%	0.587%	-0
PHARMA FUND	Nippon India Mutual Fund	40.95 L	577.08	6.09%	0.506%	+3 L
LARGE CAP FUND	Nippon India Mutual Fund	40.86 L	575.83	1.06%	0.504%	-0
Contra Fund	SBI Mutual Fund	38.37 L	540.71	1.14%	0.474%	-0
Portfolio of Kotak Flexi Cap FundNEW	Kotak Mahindra Mutual Fund	35 L	493.22	0.87%	0.432%	—

1–8 of 160

1 / 20

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Investor Presentation and earnings call

Jul 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results27 Oct 2026 · in 26 daysresults

23

Final dividend5 Jun 2026 · ex-date₹13
Final dividend27 Jun 2025 · ex-date₹13
Special dividend27 Jun 2025 · ex-date₹3
Final dividend2 Aug 2024 · ex-date₹13
Final dividend21 Jul 2023 · ex-date₹8.5
Dividend dividend8 Aug 2022 · ex-date₹5
Dividend dividend9 Aug 2021 · ex-date₹5
Special dividend19 Mar 2020 · ex-date₹1
Interim dividend19 Mar 2020 · ex-date₹3
Dividend dividend31 Jul 2019 · ex-date₹3
Dividend dividend13 Aug 2018 · ex-date₹3
Dividend dividend26 Jul 2017 · ex-date₹2
Dividend dividend12 Sept 2016 · ex-date₹2
Dividend dividend11 Aug 2015 · ex-date₹2
Dividend dividend6 Aug 2014 · ex-date₹2
Dividend dividend6 Aug 2013 · ex-date₹2
Dividend dividend1 Aug 2012 · ex-date₹2
Final dividend9 Aug 2011 · ex-date₹2
Interim dividend3 Sept 2010 · ex-date₹0.8
Dividend dividend23 Jul 2010 · ex-date₹2
Dividend dividend10 Aug 2009 · ex-date₹2
Dividend dividend12 Aug 2008 · ex-date₹2
Dividend dividend8 Aug 2007 · ex-date₹2

2

Board meeting to consider results27 Oct 2026
Board meeting to consider results23 Jul 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

38 announcementsExport CSV

28 Sept 2026, 7:15 pmBoard Meeting

Board Meeting Intimation for The Quarter And Half Year Ended 30Th September, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Exchange filing PDF

22 Sept 2026, 10:56 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Management

Change in Management PDF

18 Sept 2026, 5:32 pmCompany Update

Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

General PDF

3 Sept 2026, 8:06 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

3 Sept 2026, 4:43 pmCompany Update

Notice To Shareholders And Creditors In Accordance With NCLT Order Dated 18Th August, 2026 Regarding Merger Of Inzpera Healthsciences Limited With The Company

General PDF

2 Sept 2026, 7:57 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

31 Aug 2026, 3:42 pmCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

28 Aug 2026, 9:17 pmCompany Update

Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA

General PDF

Date	Category	Subject	Filing
28 Sept 2026, 7:15 pm	Board Meeting	Board Meeting Intimation for The Quarter And Half Year Ended 30Th September, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015	PDF
22 Sept 2026, 10:56 pm	Company Update Change in Management	Announcement under Regulation 30 (LODR)-Change in Management

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	64.6%	65%	61.6%	61%	63.7%	65.8%	67.6%	66.1%
EBITDA margin %	—	18.7%	22.2%	20.9%	22.1%	24.4%	25.9%	20.9%
EBIT margin %	—	11.9%	16.6%	16.1%	16.9%	20.3%	21.9%	16.6%
PAT margin %	9.1%	8.8%	12.5%	11.7%	12.5%	16.1%	19.1%	13.7%
Working capital
Receivable days	93	83	66	57	65	68	73	73
Inventory days	250	267	232	230	228	217	231	252
Payable days	2	5	3	8	109	102	116	123
NWC days	341	345	294	280	184	182	188	202
Leverage
Current ratio	3.29	2.66	2.87	2.99	3.34	3.7	4.24	3.44
Debt to EBITDA	—	0.88	0.41	0.18	0.1	0.04	0.01	0.04
Debt to equity	0.29	0.18	0.1	0.04	0.02	0.01	0	0.01
Interest coverage	2.8	12	21.5	35.6	39.5	66.6	111	102.1
Asset turnover	0.68	0.72	0.76	0.8	0.77	0.79	0.74	0.66
Return ratios
Return on assets %	6.2%	6.3%	9.5%	9.4%	9.6%	12.7%	14.1%	9.1%
Return on capital employed %	2.4%	12%	17.3%	17.7%	18.6%	23.1%	23.2%	16.5%
Return on equity %	9.9%	9.5%	13%	12.2%	12.1%	15.6%	16.9%	11.2%

Calls	Strike	Puts
1	0	0	₹229.6	1,160

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,741	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134	5,005	3,940
	-4,523	-1,310	-854	-1,669	104	-2,387	-1,872	-2,389	-2,988	-3,691	-2,326
	3,104	-1,326	-385	-349	-2,949	-1,330	-1,600	-958	-1,200	-1,293	-1,234
Net cash flow	322	-254	223	-326	224	38	-146	-109	-55	21	380
Free cash flow	664	2,382	757	1,331	2,496	3,126	2,782	2,397	3,036	3,843	2,341
CFO / Operating profit %	—	—	—	—	95.7%	88.3%	73.1%	64.4%	65.7%	70.2%	67%

Cipla

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Segment results

New Ventures · revenue

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Futures3

Option chain40

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Upcoming and recent1

Dividends23

Board meetings2

Announcements

Upcoming and recent1

Dividends23

Board meetings2

Ratio timeline

Announcements

Annual reports

Investor Presentation and earnings call

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Futures3

Option chain40

Profit & loss

Balance sheet

Segment results

New Ventures · revenue

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

40

1

23

2

1

23

2

3

40